ASND Stock Analysis: Buy, Sell, or Hold?
ASND - Ascendis Pharma A/S American Depositary Shares
$217.97
1.02 (0.47%)
▲
5d:
-0.04%
30d:
-6.65%
90d:
+4.3%
BUY
HIGH Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 07, 2026
Get Alerted When ASND Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ASND trading at deep discount. Market pricing in -20.6% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: ASND trading at deep discount. Market pricing in -20.6% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$542.06
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$336.58
35.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ASND is currently trading at $217.97, which is considered oversold relative to its 30-day fair value range of $221.33 to $237.34. From a valuation perspective, the stock is trading at a discount (Forward PE: 19.5) compared to its historical average (39.0). Remarkably, the market is currently pricing in an annual earnings decline of 20.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ASND is in a strong uptrend. The price is currently testing key support at $212.59. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $288.26 (+32.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ASND is in a strong uptrend. The price is currently testing key support at $212.59. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $288.26 (+32.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$221.33 -
$237.34
Company Quality Score
47/100
(HOLD)
Options IV Signal
16th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
83.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 16th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 32.9% below Wall St target ($288.26)
Fair Price Analysis
30-Day Fair Range
$221.33 -
$237.34
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$14.55
(6.7%)
Support & Resistance Levels
Support Level
$212.60
Resistance Level
$237.81
Current Trend
Strong Uptrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
19.48
Wall Street Target
$288.26
(+32.9%)
Revenue Growth (YoY)
42.3%
Profit Margin
-31.7%
Valuation Discount vs History
-20.6% cheaper
PE vs Historical
19.5 vs 39.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-20.6%
(market-implied from PE analysis)
1-Year Target
$195.26
(-10%)
2-Year Target
$175.73
(-19%)
3-Year Target
$158.16
(-27%)
3-Yr Target (if PE normalizes)
(PE: 19→39)
$316.56
(+46%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 144.4%)
$841.75
(+288%)
Base:
(SPY PE: 19.5, Growth: 144.4%)
$732.21
(+238%)
Bear:
(PE: 16.6, Growth: 144.4%)
$622.38
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 19.5 to 39.0
Stabilization Target:
$434.24
(+100.2%)
PE Expansion Potential:
+100.2%
Share & Embed Analysis
Last updated: March 30, 2026 10:10 AM ET
Data refreshes hourly during market hours. Next update: 11:10 AM
Data refreshes hourly during market hours. Next update: 11:10 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ASND showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 62 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 62 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 54 HOLD |
|
ARVN
Arvinas Inc |
BUY
21 analysts |
$15 | 55 HOLD |
|
EXEL
Exelixis Inc |
BUY
20 analysts |
$47 | 62 BUY |
